Cencora Inc COR

Thesis

Cencora is the second-largest of three U.S. pharmaceutical distributors (alongside McKesson and Cardinal Health) that together intermediate roughly 90% of the prescription drugs sold in America. The business is the textbook Buffett 'toll bridge': pharmaceutical manufacturers ship drugs in, retail pharmacies, hospitals, and physician practices pull drugs out, and Cencora collects a fixed-fee or buy-side margin on each unit moved. Volume tracks demographics (an aging population), specialty/biologic mix shift (which carries higher dollar-per-pill economics), and contractually-locked customers like Walgreens, Cencora's anchor partner that owns ~17% of the equity and contributes roughly a third of revenue. The economics on display in the scorecard are deceptive in both directions. Headline ROIC is just 4.27% (10y average), which looks pedestrian — but distributors deliberately run on negative working capital (they collect from pharmacies before paying manufacturers), so reported invested capital understates the true capital-light nature of the franchise. ROIIC over five years is 90.4% and FCF conversion is 1.81x net income, both consistent with a business that grows revenue faster than it consumes cash. Net debt/EBITDA of 1.86x and a 1.3% reduction in share count over a decade reflect disciplined capital allocation. The catch is price. At $304, COR trades at 42.5x TTM earnings against a 10-year average of 26.6x — a ~60% premium. The scorer's intrinsic value range is materially negative ($-158 / $-112 / $-70) because owner-earnings TTM are negative ($-578M) once full capex (Alliance Healthcare integration, World Courier expansion, technology) is treated as maintenance. The scorer flagged maintenance-capex uncertainty and clamped the base CAGR. This is a quality business at a price that requires either a normalization of capex or significantly higher steady-state cash generation to justify. Owning it makes sense closer to $230 (back to the 10y multiple on normalized earnings); above $340 even the bull case is mostly priced in.

Moat

Cencora's moat is a combination of cost advantage, switching costs, and intangible regulatory infrastructure — none of which alone is wide, but layered together they produce a durable oligopoly position.

Cost advantages (primary). Drug distribution is a pure-scale business. Cencora moves roughly $300B of pharmaceuticals per year through ~50 distribution centers, negotiating buy-side rebates, generic launch economics, and inventory financing terms that no sub-scale entrant can match. As Damodaran writes [3], 'In businesses, where scale can be used to reduce costs, economies of scale can give bigger firms advantages over smaller firms.' This applies with exceptional force here because gross margins are ~3% — a 50bp cost disadvantage is the entire profit pool. The Big 3 (Cencora, McKesson, Cardinal) collectively control ~90% of U.S. drug distribution; a fourth competitor would need to replicate ~$50B of distribution-center capex and contract relationships with thousands of manufacturers and pharmacies before earning a dollar. The $10B/5-year stress test [from canon framework] decisively fails for an entrant: $10B builds maybe a regional player but cannot dent the cost gap.

Switching costs (meaningful but contractual rather than technical). Cencora's relationship with Walgreens is governed by a long-dated supply agreement (extended through 2029) under which Cencora is the primary distributor. For a community pharmacy or hospital system, switching distributors means re-platforming ordering systems, re-papering contracts with hundreds of manufacturers via the new distributor's GPO, and accepting working-capital risk during transition. Damodaran's framing of switching costs [2] — 'the most significant barrier to entry... is the cost to the end-user of switching' — applies directly. The downside: switching costs are between the Big 3, not against them. Walgreens, CVS, and large IDNs periodically re-bid distribution contracts and have used those auctions to compress distributor margins.

Intangibles — regulatory and licensing. Pharmaceutical wholesaling requires DEA registration, state-by-state licensure, DSCSA serialization compliance, controlled-substance handling, and increasingly, opioid suspicious-order monitoring under the 2022 settlement consent decrees. New entrants face a multi-year regulatory build, not an open door. Cencora additionally owns specialty businesses (World Courier for cold-chain biologics, MWI Animal Health, Alliance Healthcare in Europe) where regulatory and logistics complexity is a higher barrier than commodity drug distribution.

Network effects (weak/none). Distributors are hub-and-spoke; there is no two-sided network that strengthens with more participants in a Metcalfe-law sense.

Pricing power (limited). This is the moat's weakness. Cencora is a price-taker on both sides: manufacturers set wholesale acquisition cost, and large customers (Walgreens, Express Scripts, hospital GPOs) negotiate distribution fees aggressively. Buffett would note [4] that the See's Candy test — 'can you raise price 10%?' — fails. Cencora's pricing power exists only via mix shift toward specialty/biologic drugs where the dollar-per-handling economics are richer.

Erosion risks. Three credible threats: (1) Amazon Pharmacy / direct-to-consumer manufacturer models bypassing the wholesaler; (2) GLP-1 and biologic drugs increasingly being shipped via specialty pharmacies or 340B pathways with thinner distributor cuts; (3) opioid liability creating recurring legal/political overhang despite the 2022 master settlement (~$6.4B already accrued). Damodaran [6] reminds us 'there is a tendency, albeit slow, for the returns at companies to converge on industry averages' — and pharma distribution is already at low industry-average returns; the question is whether the oligopoly structure prevents further compression. So far it has, for two decades.

Moat verdict: NARROW. Wide enough that the Big 3 structure has held since the 1990s, narrow enough that ROIC has never been excellent and customer power keeps margins capped. This is Mayo Clinic durability [4] without Mayo Clinic economics.

Management & Capital Allocation

Cencora's capital-allocation track record under CEO Bob Mauch (who succeeded long-tenured Steve Collis in late 2024) and CFO Jim Cleary is solid but not exceptional, and the recent shift toward larger M&A introduces execution risk that has not yet been earned out.

Reinvestment in the core (B+). Maintenance capex on distribution centers, automation, and DSCSA-compliant serialization is non-discretionary and the company has invested consistently. Specialty (biologics cold chain via World Courier) and animal health (MWI) are higher-return adjacencies that Cencora has been correct to lean into. Capex/sales has remained disciplined at roughly 0.2-0.3% — extraordinarily low because the business is asset-light relative to revenue. The scorer's note that 'maintenance capex uncertain (>50% spread)' reflects that recent capex has been elevated by the Alliance Healthcare integration and is hard to disentangle from growth capex; this is a real but not damning ambiguity.

**Acquisitions (B-, watch). The 2021 acquisition of Walgreens' Alliance Healthcare for $6.5B doubled European exposure and was the largest deal in the company's history. Initial integration has produced reasonable accretion but has also leveraged the balance sheet (net debt/EBITDA 1.86x, up from sub-1x pre-deal) and added a lower-margin geography. The 2024 acquisition of Retina Consultants of America ($4.6B) is more interesting — a vertical move into specialty practice ownership — but it pulls Cencora outside its pure-distributor circle of competence. I want two more years of evidence before grading this confidently.

**Debt (B). Cencora has used investment-grade debt opportunistically and the leverage profile (1.86x net debt/EBITDA) is conservative for a stable-cash-flow distributor. Interest coverage is not in the scorecard but is comfortable. The 364-day term loan facility cited in recent filings is a sensible bridge structure for the RCA acquisition. No reckless leverage.

**Buybacks (A-). Share count is down 1.3% over ten years, modest but the pattern matters: buybacks have accelerated when the stock has been weak (2018, 2022 opioid-overhang lows) and slowed when it has been strong, suggesting some price discipline. I do not have the historical avg-P/IV-when-buying number cleanly, but the pattern is consistent with management understanding that buybacks below intrinsic value create per-share value. At today's 42.5x P/E, I would prefer they slow buybacks.

**Dividends (B). A modest growing dividend (~1% yield) is appropriate for a low-ROIC, capital-light cash-flow business; the company has raised the dividend each year for over 15 years. Not a primary capital-allocation lever but signals discipline.

**Communication quality (B). 10-K and proxy disclosures are clear on segment economics, opioid reserve roll-forwards, and the Walgreens relationship. Management does not over-promise; guidance is conservative and usually beaten. Earnings calls are operationally focused, light on strategic vision, which I read as a feature not a bug for a distribution business. The 2023 corporate rebrand from AmerisourceBergen to Cencora was an unforced and expensive identity exercise — a small but real demerit.

**Walgreens ownership (special factor). WBA owns ~17% of Cencora and has historically been an influential but constructive shareholder. WBA's own financial distress under private-equity transition introduces uncertainty: if WBA forces a block sale, it creates a technical overhang; if WBA modifies the supply agreement at the 2029 renewal, it could compress economics. Management has navigated this delicately so far.

Capital allocator: B. Disciplined, shareholder-aligned, with one large recent acquisition (RCA) that I cannot yet grade. Not the A-grade allocators of a Markel or Constellation Software, but well above the median S&P industrial.

Industry Structure

U.S. pharmaceutical distribution is one of the most consolidated industries in the economy and the Five Forces analysis explains both why returns have been stable for two decades and why they have never been spectacular.

Threat of new entrants — LOW. The Big 3 (Cencora ~32%, McKesson ~35%, Cardinal Health ~25%) control roughly 90% of U.S. prescription drug distribution by revenue. A new entrant must build $50B+ of distribution capacity, secure DEA and 50-state wholesaler licenses, comply with DSCSA serialization, sign supply agreements with thousands of manufacturers, and accept negative working capital economics during ramp — all to earn 1-2% operating margins on commodity products. Amazon has pursued retail pharmacy (Amazon Pharmacy / PillPack) but has not entered wholesale distribution because the moat is real. Verdict: very low threat over a 10-year horizon.

Bargaining power of suppliers — MODERATE-HIGH. Pharmaceutical manufacturers (Pfizer, Merck, Lilly, Novartis, etc.) set the wholesale acquisition cost (WAC) and increasingly use direct-to-pharmacy programs for high-cost specialty drugs (the 'specialty carve-out' phenomenon). Manufacturers can in principle bypass distributors for high-value low-volume drugs, and have done so partially. The countervailing fact is that most manufacturers do not want the working-capital, regulatory, and logistics burden of selling to ~70,000 retail pharmacies and hospitals directly — the distributor exists because it is genuinely cheaper for both sides. Net: suppliers have leverage at the margin but cannot disintermediate at scale.

Bargaining power of buyers — HIGH. This is the binding constraint on distributor returns. The customer base has consolidated dramatically: three retail pharmacy chains (CVS, Walgreens, Walmart) plus a handful of national IDNs and PBMs account for the majority of distribution volume. Walgreens alone is roughly a third of Cencora's revenue and also owns ~17% of the equity — an unusual structure that creates both stability and concentration risk. Every contract renewal cycle features fee compression. This is why ROIC sits at 4.27% rather than the 15%+ a true wide-moat business commands.

Threat of substitutes — LOW-MODERATE. Substitutes are: (a) manufacturer-direct distribution for specialty drugs (real but limited share), (b) specialty pharmacies handling biologics outside traditional wholesale (growing share, lower distributor cut), (c) 340B and government direct programs (existing carve-out, slow growth), (d) hypothetical Amazon-style direct-to-consumer disruption (talked about for a decade, has not materialized in wholesale). The mix is shifting toward specialty, which structurally lowers distributor share-of-economics per drug dollar. This is a slow erosion, not an inflection.

Industry rivalry — MODERATE. The Big 3 compete rationally rather than ruinously. They have largely stopped fighting on price for marginal customer wins and instead compete on service capabilities (specialty handling, technology platforms, packaging services, consulting). The 2018-2020 period of contract-renewal price compression with Walgreens/CVS/Express Scripts appears to have stabilized. Implicit oligopoly discipline is visible in the consistent ~3% gross margin band each player runs.

Value pool location and trajectory. The bulk of U.S. healthcare value is captured by manufacturers (high margins on novel drugs), PBMs (rebate spreads), and to a lesser extent retail pharmacies. Distributors capture the smallest slice of every dollar. The trajectory: stable in absolute dollars (volume + drug-price growth), declining in percentage share (specialty mix shift, manufacturer-direct programs). This is a 'volume grows, take rate slowly compresses' setup — survivable but not a tailwind.

Industry Verdict: Good. Stable oligopoly, predictable economics, low disruption risk over 10 years, but structurally capped returns prevent an 'Excellent' rating. This is a good business to own at the right price, not a great one at any price.

Inversion (Bear Case)

I am now short Cencora. My target is $180 within three years. Here is how this plays out.

1. The single event that kills this — Walgreens forces a renegotiation or restructures the equity stake. Walgreens Boots Alliance is in the worst financial condition of its modern history. Same-store sales are flat, the U.S. retail pharmacy footprint is being aggressively closed (1,200+ stores), and the company is exploring a take-private transaction with Sycamore Partners. Walgreens is roughly a third of Cencora's revenue and owns ~17% of the equity. Two scenarios both end badly: (a) Sycamore-style PE owners renegotiate the supply agreement at 2029 renewal and extract 100-200bp of margin from Cencora, permanently; (b) WBA monetizes its Cencora stake to fund the take-private, putting ~33M shares (roughly 18 days of average daily volume at full sale) into the market. Either path compresses both earnings and the multiple. The bull case implicitly assumes Walgreens stays the same friendly anchor it has been since 2013 — that is no longer a safe assumption.

2. Why the moat is narrower than bulls think. ROIC of 4.27% over ten years is the moat speaking. A wide-moat business should generate 15%+ ROIC. Cencora generates the ROIC of a regulated utility because it has the pricing power of a regulated utility — squeezed between concentrated manufacturers and concentrated buyers. Bulls point to the Big 3 oligopoly as evidence of a moat; in fact the oligopoly is the moat, and the moat protects Cencora from being competed out of business, not from being competed down to thin margins. Specialty drug mix shift is making this worse, not better: as more drugs ship via specialty pharmacy channels and manufacturer-direct programs, the distributor's slice of each healthcare dollar shrinks. Amazon's slow build of pharmacy capabilities is the next wave; it does not need to 'win' — it just needs to provide one more credible customer alternative for the next contract round.

3. Why management is worse than it appears. The 2024 acquisition of Retina Consultants of America for $4.6B took Cencora outside its circle of competence into ophthalmology practice ownership — a doctor-management business with regulatory exposure (340B, Medicare reimbursement) and labor-cost dynamics that the distribution business does not share. The Alliance Healthcare integration (acquired 2021) is still consuming capex and management bandwidth four years in. The 2023 rebrand from AmerisourceBergen to Cencora cost real money and signal-distorted what is fundamentally a B2B logistics company. The new CEO (Mauch, late 2024) has yet to be tested in a downturn or a Walgreens crisis. Management's calmness around the Walgreens situation reads to me as complacency rather than competence; the right response would be aggressive diversification of the customer base, which I do not see.

4. What bulls are extrapolating that won't hold. Bulls are extrapolating: (a) GLP-1 volume tailwind continues at current pace — but GLP-1 economics are unusually unfavorable to distributors because manufacturers (Lilly, Novo) are exploring direct-to-consumer programs and the dollar volume is concentrated rather than fragmented; (b) opioid liability is fully reserved — but state attorneys general are pursuing follow-on cases on tribal lands, municipalities outside the master settlement, and a parallel track on benzodiazepines; (c) the 42.5x P/E reflects 'quality re-rating' rather than peak earnings — but TTM owner earnings are already negative ($-578M per the scorecard), meaning the multiple is even more demanding on normalized numbers; (d) buybacks will continue to flatter EPS — but at 42.5x earnings, buybacks destroy per-share value. The scorer's IV range is negative: $-158 / $-112 / $-70. That is not a number a stock at $304 should ignore.

5. Valuation trap (multiple compression / regime change). The 10-year average P/E is 26.6x. The current P/E is 42.5x. If multiple normalizes to 26.6x on flat earnings, the stock is worth ~$190. If earnings re-rate down 10% on Walgreens contract pressure or a specialty mix-shift hit, and the multiple normalizes simultaneously, the stock is worth ~$170. The catalyst for that re-rating exists: rising rates have already started compressing high-multiple stable-business stocks, and Cencora's premium to historical multiple is the most extreme it has been outside the 2021 zero-rate bubble. There is no fundamental reason a low-ROIC, customer-concentrated, mid-single-digit-grower distributor should trade at a 60% premium to its own decade-long multiple.

If I am right, the stock could be worth $180 within three years.

Lollapalooza Bias Check

Several biases are pulling me toward a more bullish read than the numbers support, and I should name them explicitly.

Authority/social proof. Cencora is widely held by quality-focused institutional investors (the company has appeared in numerous compounder portfolios over the last decade), and it scores 70/100 on a quality-focused composite. The phrase 'Big 3 distributor oligopoly' has acquired talisman status — analysts repeat it as a moat assertion without re-examining whether it produces excellent unit economics (it doesn't, ROIC is 4.27%). I am partially anchored by the consensus that this is a 'wonderful business,' which has caused me to underweight the customer-concentration and specialty-mix-shift threats.

Anchoring on the IV range. The scorer's IV range ($-158 / $-112 / $-70) is so negative it almost demands to be argued away. My instinct on first read was 'the model must be wrong because the business is obviously not worth less than zero.' That instinct may be partially correct (negative TTM owner earnings reflect transitional capex, not steady-state economics) but it is also partially the deprival super-reaction tendency at work — I am reluctant to surrender the framing that this is a real compounder.

Recency bias around Walgreens. Walgreens' recent distress is salient and dominates headlines, which can either over- or under-weight the threat depending on direction. My current read is that the threat is real but probably contained because (a) WBA needs Cencora's working capital arrangement to continue operating, and (b) any new owner (Sycamore or other) needs distribution continuity through a multi-year transition. But I notice I am reaching for arguments that minimize the threat — that is recency bias trying to revert to the prior comfortable narrative.

Confirmation bias on capital allocation. I rated capital allocation B, and on review the evidence for that B grade is mostly the absence of disasters rather than the presence of excellent decisions. The RCA acquisition could be excellent or could be a category error; I do not know yet, and I should be honest that my B rating partly reflects giving the benefit of the doubt to a company I find structurally interesting.

Commitment / consistency on the 'quality at a price' framework. I have written a thesis that says 'good business at the right price,' which commits me to identifying a price at which I would buy. That commitment can pull me toward picking a target price that is reachable in some plausible scenario rather than the price the math actually supports. The honest answer is that the scorer's IV range is so negative the price at which I would buy with conviction is well below $230 — possibly $180 — and I should not soften that to make the recommendation more actionable.

Incentive (none directly, but worth flagging). I have no position and no compensation tied to this view, so direct incentive bias is absent. The relevant incentive is the analyst's natural pull toward producing a definite recommendation rather than 'wait and see,' which biases me toward Hold rather than Avoid.

10-Year Outlook

In ten years, will Cencora be a fundamentally similar business? Almost certainly yes — a national pharmaceutical distributor with the same Big-3 structure, the same customer mix (large pharmacy chains, IDNs, independent pharmacies), the same regulatory framework (DEA, DSCSA, state licensure), and the same negative-working-capital economics. The hub-and-spoke physical distribution of pharmaceuticals is a 50-year-old business model and there is no credible technology vector that obsoletes it within a decade.

Will the customer base be larger? Probably yes in dollar terms, modestly yes in volume terms. U.S. pharmaceutical spending is forecast to grow 4-6% annually nominally, driven by aging demographics, biologic mix, and new categories (GLP-1s, gene therapies, oncology). Cencora should participate proportionally to its ~32% market share. The customer count may shrink as retail pharmacy consolidates further (Walgreens closures, independent pharmacy attrition), but the dollar-volume per surviving customer rises.

Will profit per customer be higher? This is the hard question. Specialty drug mix shift compresses distributor take rates; manufacturer-direct programs (Lilly Direct, similar) compress them further; PBM and large-pharmacy negotiation compresses them further. The countervailing force is that absolute drug-handling volumes rise, and Cencora's specialty/cold-chain capabilities (World Courier) capture incremental value. My honest read is that profit per customer ten years out is roughly flat in real terms — neither a tailwind nor a collapse.

Will the moat be wider? Probably not. The moat is structural (Big-3 scale, regulatory complexity), not improving. New entrants are not threatening, but customer power and specialty disintermediation are slowly chipping at the moat. A flat moat in a stable industry is acceptable; a flat moat at 42.5x earnings is not.

The single biggest threat over ten years: customer-side disruption. Either Amazon Pharmacy reaches scale, or large IDNs/PBMs vertical-integrate distribution, or Walgreens' restructuring removes a third of revenue. Any one of these is survivable; two together would be material.

The ten-year picture is a slow-grower with stable structure and modest compression — a roughly 6-8% total-return business at fair price. That is not a CONFIDENCE: high setup at $304. The structural prediction is high-confidence; the return prediction at this entry price is medium-confidence because so much depends on multiple normalization timing.

CONFIDENCE: medium